‘Amyvid is the first test that may effectively rule out Alzheimer’s disease in individuals who are becoming evaluated for cognitive impairment,’ Ethan Spiegler, M.D., chief of nuclear medicine at Advanced Radiology and plank certified radiologist. ‘The ability to persuasively rule out AD might help physicians treat other causes of cognitive impairment and help family members better plan for the future of themselves.’.. Advanced Radiology to provide Amyvid for detection of AD Advanced Radiology, a division of RadNet, Inc., a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 237 fully-owned and operated outpatient imaging centers, announced it will be one of a small amount of imaging centers in the U.S.Within the program, Afraxis will partner with the NIH to pursue the ongoing advancement of the business’s disease-modifying treatments for Fragile X syndrome. Fragile X syndrome is a rare genetic disorder that is the most common inherited form of mental retardation. TRND collaborations help companies concentrating on rare and neglected diseases conquer one of the biggest obstacles facing all drug development companies: advancing applications through that ‘valley of death’ between identification of a promising compound, and clinical stage advancement when a scheduled plan becomes more attractive to a big pharma partner, stated Jay Lichter, Ph.D., cEO and president of Afraxis.